Bank of America Reiterates Buy Rating on Aegerion Pharmaceuticals Following ACC Meeting
In a report published Monday, Bank of America reiterated its Buy rating and $42.00 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR).
Bank of America noted, “Familial hypercholesterolemia (FH) was a highly visible topic at this weekend's American College of Cardiology (ACC) meeting in San Francisco. AEGR's recently approved Juxtapid (lomitapide) and its ultra-orphan indication homozygous FH (HoFH) were discussed in depth at a lipid lowering therapeutics symposium. Physicians from the US and abroad noted the need for therapies beyond apheresis to treat HoFH. A presenter from the Netherlands described the greater use of genetic testing in that country that indicated the assumed prevalence of one in one million for HoFH could be outdated and may be closer to one in 250K (equates to 1,200 HoFH and 1.2mn HeFH in the US).”
Aegerion Pharmaceuticals closed on Friday at $36.90.
Latest Ratings for AEGR
|Feb 2016||Bank of America||Downgrades||Neutral||Underperform|
|Dec 2015||Guggenheim Securities||Upgrades||Sell||Buy|
|Nov 2015||Bank of America||Upgrades||Underperform||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.